Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Background:
Small cell lung cancer (SCLC) and high-grade neuroendocrine cancers (HGNEC) are aggressive
neuroendocrine cancers. At first, SCLC and HGNEC respond to chemotherapy. But then they
relapse quickly and become resistant to treatment. Researchers want to see if a combination
of drugs can help.
Objective:
To see if the combination of lurbinectedin and berzosertib may be effective to shrink SCLC
and HGNEC tumors, and to find the best dose of the combination.
Eligibility:
Adults ages 18 and older with a solid tumor, SCLC, or HGNEC.
Design:
Participants will get lurbinectedin by intravenous (IV) catheter on Day 1 of each cycle (1
cycle = 21 days). They will get berzosertib by IV on Days 1 and 2 of each cycle.
Participants will continue to receive treatment as long as they are benefiting from
treatment.
Participants will have physical exams and blood tests. Their symptoms, medicines, and ability
to perform their normal activities will be reviewed.
Participants will have electrocardiograms to test heart function. Sticky pads will be placed
on their chest, arms, and legs.
Participants will give blood and hair samples for research. They may have optional tumor
biopsies.
Participants will have computed tomography (CT) scans to see if the treatment is effective.
Participants will have a follow-up visit 1 month after treatment ends. Then they will be
followed by email or phone for the rest of their life.